This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bundesministerium der Finanzen (2004a): AfA-Tabelle für die allgemein verwendbaren Anlagegüter. Quelle: http://www.bundesfinanzministerium.de/dokumente/ix-..15472/Artikel.htm, letzter Zufgriff 27.08.2004
Bundesministerium der Finanzen (2004b): Sachkostenpauschale eines Arbeitsplatzes in der Bundesverwaltung. Quelle: http://www.bundesfinanzministerium.de/dokumente/ix-..1844/Artikel.htm, letzter Zufgriff 27.08.2004
Cromwell D.M (1998): Cost Analysis of Alternative Approaches to Colorectal Screening in Familial Adenomatous Polyposis. Gastroenterology 114: 893–901
Europäisches Patentamt (2004): „Myriad/breast cancer“ patent revoked after public hearing. Pressemitteilung vom 18.05.2004. Quelle: http://www.european-patent-office.org/news/pressrel/2004_05_18_e.htm, letzter Zugriff 24.08.2004
German consortium of hereditary breast and ovarian cancer (2002). Comprehensive Analysis of 989 Patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the german population. Int J Cancer 97: 472–480
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI (1999) Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol. 17:494–500
Griffith GL, Edwards RT, Gray J (2004) Cancer genetics services: a systematic review of the economic evidence and issues. Br J Cancer. 90:1697–703
Institut für Arbeitsmarkt-und Berufsforschung (IAB) (2004) Kurzbericht Nr. 5 Quelle: http://www.iab.de/asp/internet/dbdokShow.asp?pkyDoku=k040315n01, letzter Zufgriff 27.08. 2004
Lawrence WF, Peshkin BN, Liang W, Isaacs C, Lerman C, Mandelblatt JS (2001) Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev. 10:475–81
National Institute for Clinical Excellence, London. (2004) NICE Clinical Guideline 14: Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care.
Sevilla C (2003) Evaluation economique des innovations biomedicales: l’exemple de la diffusion des tests genetiques en oncologie. Diss. (Marseille)
Sevilla C, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, Sobol H, Moatti JP (2003) Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing. Int J Technol Assess Health Care. 19: 287–300
Tengs TO, Berry DA (2000) The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Dis. Manag. Clin. Outcomes. 1: 15–24
Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, Nagengast FM, Menko FH, Meera Khan P (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer. 82:1632–7
Wallace AJ, Wu CL, Elles RG (1999) Meta-PCR: A novel method for creating chimeric DNA molecules and increasing the productivity of mutation scanning techniques. GenetTest. 3: 173–83
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Haverkamp, A., Gerhardus, A., Krauth, C. (2005). Kosten der genetischen Beratung und der molekulargenetischen Diagnostik bei BRCA-Mutationen. In: Gerhardus, A., Schleberger, H., Schlegelberger, B., Schwartz, F.W. (eds) BRCA — Erblicher Brust- und Eierstockkrebs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26553-8_4
Download citation
DOI: https://doi.org/10.1007/3-540-26553-8_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-24441-7
Online ISBN: 978-3-540-26553-5
eBook Packages: Medicine (German Language)